Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00082459
Recruitment Status :
(Lack of enrollment)
The goal of this trial is to determine the safety of HSPPC-96 and which route of administration achieves a better response with the vaccine. HSPPC-96 is an immunotherapeutic agent made from an individual patient's tumor.
Condition or disease
Renal Cell Carcinoma
Biological: autologous human tumor-derived HSPPC-96
The goal of this trial is to determine the safety of HSPPC-96 and which route of administration achieves a better response with the vaccine. HSPPC-96 is an immunotherapeutic agent made from an individual patient's tumor. The study is being conducted in Houston, Texas with patients enrolled into one of two treatment arms. The two treatment arms are either subcutaneous injection or intradermal injection, both with HSPPC-96. To be treated with HSPPC-96 patients must undergo surgery to remove the kidney tumor and a portion of this tissue will be sent to Antigenics' manufacturing facility for processing.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
No previous therapy for metastatic renal cell carcinoma
Measurable disease (RECIST criteria)
Primary tumor greater than or equal to 7cm on CT or MRI
ECOG performance status 0-1
At least 18 years old
Life expectancy > 3 months
Adequate cardiac function (NYHA I-II)
Provide written informed consent
Absence of multiple liver metastases, brain or threatening bone metastases (axial skeleton and/or pathological features)
Planned complete nephrectomy
History of primary or secondary immunodeficiency, or patients using systemic corticosteroids or cyclosporin A
Other cancer (including renal cell carcinoma) within the last five years (with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin)
Embolization of the renal artery prior to nephrectomy
Active, uncontrolled infection or other serious medical illnesses, preventing study completion, in the opinion of the Principal Investigator